| Date | Title | Description |
| 06.09.2016 | Nevro Announces Two-Year SENZA-RCT Results in Neurosurgery | Redwood City, CA — Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced the publication of long-term data for the treatment of chr... |
| 13.06.2016 | Nevro Announces Full Exercise of Over-Allotment Option and Closing of Public Offering of $172.5 M Convertible Senior Notes | Redwood City, CA — Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced the closing of its previously announced offering, register... |
| 06.06.2016 | Nevro Announces Proposed Public Offering of $125 Million Convertible Senior Notes | Redwood City, CA — Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it intends to offer, subject to market conditions and... |
| 15.04.2016 | Nevro Receives FDA Approval for New Surgical Leads for the Senza Spinal Cord Stimulation System | Redwood City, CA — Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it has received U.S. Food and Drug Administration ( FD... |
| 08.05.2015 | Nevro Receives FDA Approval for Senza® Spinal Cord Stimulation System | Menlo Park, CA — Nevro Corp. NVRO, -0.70% a medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it has received approval from the United States Food and Drug A... |
| 11.03.2014 | Nevro Corp. Announces Publication of 24-month European Clinical Data on HF10 Spinal Cord Stimulation (SCS) Therapy for Chronic Back and Leg Pain | Menlo Park, CA — Nevro Corp. announced today that the 24 month results of a prospective European clinical study using Nevro’s Senza® system delivering HF10™ therapy were published in the journal Pain Medicine. The study was conducted in the... |
| 08.10.2013 | Bay City Capital Names Ashley Ledbetter Dombkowski, PhD, Managing Director | San Francisco, CA — Bay City Capital, a leading venture capital firm focused on early-stage to growth equity investments in the life sciences, today announced Ashley Dombkowski, Ph.D. joined as Managing Director.
“Drug discovery and develo... |
| 24.01.2013 | Nevro Announces Issuance of Additional Key U.S. Patents for Innovative Chronic Pain Treatment | January 24, 2013
Menlo Park, CA — Nevro Corp., a medical device company focused on improving the lives of patients suffering from debilitating chronic pain, announced today the issuance of four additional key patents related to the company... |
| 01.10.2008 | Nevro raises $22 million for pain therapy | Nevro Corp. has raised $22 million in a first round of funding. The Palo Alto, Calif. company is conducting clinical trials for its neuromodulation therapy for chronic pain. New investor Accuitive Medical Ventures joined return investors Ab... |
